Literature DB >> 7554699

Propranolol disposition in Chinese subjects of different CYP2D6 genotypes.

M L Lai1, S L Wang, M D Lai, E T Lin, M Tse, J D Huang.   

Abstract

Propranolol pharmacokinetics among different genotypes of CYP2D6 was compared in this study. The Chinese (Han) population consisted of 44 healthy unrelated individuals living in southern Taiwan. Endonuclease tests based on polymerase chain reaction were used to determine C/T188 genotypes of CYP2D6 in leukocyte deoxyribonucleic acid. Based on codon 188 genotypes, subjects were categorized into three groups: homozygous C/C188 (n = 13), heterozygous C/T188 (n = 14); and homozygous T/T188 (n = 17). Each subject was given a 40 mg propranolol tablet. Blood samples were drawn before and 12 hours after propranolol administration to measure propranolol and 4-hydroxypropranolol. Three genotypes showed distinct time profiles of plasma propranolol and 4-hydroxypropranolol. The area under plasma concentration curve values (mean +/- SEM), were 322.0 +/- 40.8, 481.6 +/- 77.5, and 766.1 +/- 92.8 nmol.hr/L, respectively, for C/C188, C/T188, and T/T188 subjects (p < 0.05). The 48-hour excreted amount of 4-hydroxy-S-propranolol-O-glucuronide, but not 4-hydroxy-R-propranolol-O-glucuronide, was significantly higher for C/C188 than for T/T188 subjects (p < 0.05). This study shows a different propranolol disposition in Chinese subjects of different CYP2D6 genotypes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7554699     DOI: 10.1016/0009-9236(95)90242-2

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes.

Authors:  C Senda; Y Yamaura; K Kobayashi; H Fujii; H Minami; Y Sasaki; T Igarashi; K Chiba
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

Review 2.  Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.

Authors:  T Yokoi; T Kamataki
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

3.  Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: a look at CYP2D6 metabolising variants.

Authors:  Narendranath Epperla; Murray H Brilliant; Humberto Vidaillet
Journal:  BMJ Case Rep       Date:  2014-02-11

4.  Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.

Authors:  T Fukuda; I Yamamoto; Y Nishida; Q Zhou; M Ohno; K Takada; J Azuma
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

5.  Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia.

Authors:  Junji Saruwatari; Masayuki Matsunaga; Kazuyuki Ikeda; Masashi Nakao; Kentaro Oniki; Takayuki Seo; Shuichi Mihara; Toru Marubayashi; Tetsuya Kamataki; Kazuko Nakagawa
Journal:  Eur J Clin Pharmacol       Date:  2006-11-07       Impact factor: 2.953

6.  Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers.

Authors:  Masahiro Otani; Tsuyoshi Fukuda; Masakazu Naohara; Hiromi Maune; Chiaki Senda; Isamu Yamamoto; Junichi Azuma
Journal:  Eur J Clin Pharmacol       Date:  2003-08-23       Impact factor: 2.953

Review 7.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians.

Authors:  P Dalén; M-L Dahl; H-K Roh; G Tybring; M Eichelbaum; G R Wilkinson; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2003-06       Impact factor: 4.335

Review 9.  Pharmacogenetic factors affecting β-blocker metabolism and response.

Authors:  Cameron D Thomas; Julie A Johnson
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-09-09       Impact factor: 4.481

10.  Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma.

Authors:  Tomoki Takechi; Tadao Kumokawa; Rumiko Kato; Takeshi Higuchi; Tsuyoshi Kaneko; Ichiro Ieiri
Journal:  J Clin Pharmacol       Date:  2018-05-10       Impact factor: 3.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.